HARBOUR BIOMED
Edit

HARBOUR BIOMED

http://www.harbourbiomed.com/
Last activity: 30.04.2024
Categories: InformationLifePlatformTechnologyBuildingDevelopmentHuman
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions. The Company’s proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com
Followers
1.97K
Mentions
52
Location: United States, Massachusetts, Cambridge
Employees: 201-500
Total raised: $262.89M
Founded date: 2016
LinkedIn
Email

Investors 1

Funding Rounds 3

DateSeriesAmountInvestors
10.07.2020Series C$102.8M-
13.03.2020Series B$75.09M-
27.08.2018Series B$85M-

Mentions in press and media 52

DateTitleDescriptionSource
30.04.2024HanAll Biopharma Reports Q1 2024 Financial Results and Provi...Delivered solid performance to start 2024, with record-breaking first quarter revenue of 34.1 billio...en.prnasia...
28.03.2024Harbour BioMed Reports Full Year 2023 Financial ResultsCAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, March 28, 2024 /PRNewswire/ -- Harbour B...salamancap...
28.03.2024Harbour BioMed Reports Full Year 2023 Financial ResultsCAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, March 28, 2024 /PRNewswire/ -- Harbour B...en.prnasia...
21.03.2024HanAll Biopharma Reports Full-Year 2023 Financial Results an...Full-year 2023 net revenue reaches 135 billion KRW, driven by strong sales growth. R&D momentum ...en.prnasia...
24.01.2024Harbour BioMed Announces IND Clearance for HBM9027 in the U....CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Jan. 24, 2024 /PRNewswire/ -- Harbour Bi...en.prnasia...
19.01.2024Harbour BioMed Announces Positive Profit AlertCAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Jan. 19, 2024 /PRNewswire/ -- Harbour Bi...en.prnasia...
28.08.2023Harbour BioMed Announces 2023 Interim ResultsCAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2023 /PRNewswire/ -- Harbour Bi...en.prnasia...
08.08.2023Harbour BioMed Appoints Dr. Albert R. Collinson as Independe...CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 8, 2023 /PRNewswire/ -- Harbour Bio...en.prnasia...
13.07.2023Harbour BioMed Announces 2023 Interim Results Positive Profi...CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, July 13, 2023 /PRNewswire/ -- Harbour Bi...en.prnasia...
29.06.2023Harbour BioMed Announces Biologics License Application Accep...CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, June 29, 2023 /PRNewswire/ -- Harbour Bi...en.prnasia...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In